|
Bone Diseases, Metabolic
|
C18.452.104 |
|
|
Radioimmunotherapy
|
E02.815.520 |
|
|
Receptor, IGF Type 2
|
D12.776.543.750.750.400.780.410 |
|
|
Alcohol-Related Disorders
|
C25.775.100 |
|
|
Azotobacter
|
B03.440.400.425.625.050 |
|
|
Hydatidiform Mole
|
C13.703.720.949.416.875 |
|
|
Photoreceptor Cells, Invertebrate
|
A08.800.950.937.650 |
|
|
Amodiaquine
|
D03.633.100.810.050.060 |
|
|
I-kappa B Kinase
|
D051550 |
[A protein serine-threonine kinase that catalyzes the PHOSPHORYLATION of I KAPPA B PROTEINS. This enzyme also activates the transcription factor NF-KAPPA B and is composed of alpha and beta catalytic subunits, which are protein kinases and gamma, a regulatory subunit.
] |
|
beta-Adrenergic Receptor Kinases
|
D051552 |
[G-protein-coupled receptor kinases that mediate agonist-dependent PHOSPHORYLATION and desensitization of BETA-ADRENERGIC RECEPTORS.
] |
|
Autosomal Emery-Dreifuss Muscular Dystrophy
|
C05.651.534.500.350.250 |
|
|
Cerebral Amyloid Angiopathy, Familial
|
C18.452.845.500.100.160 |
|
|
Varicocele
|
C12.294.936 |
|
|
Centromere Protein B
|
D12.776.664.235.199 |
|
|
Hyperbilirubinemia, Neonatal
|
D051556 |
[Accumulation of BILIRUBIN, a breakdown product of HEME PROTEINS, in the BLOOD during the first weeks of life. This may lead to NEONATAL JAUNDICE. The excess bilirubin may exist in the unconjugated (indirect) or the conjugated (direct) form. The condition may be self-limiting (PHYSIOLOGICAL NEONATAL JAUNDICE) or pathological with toxic levels of bilirubin.
] |
|
Tobacco
|
B01.650.940.800.575.912.250.908.500.900 |
|
|
Hepatocyte Nuclear Factor 4
|
D051557 |
[A subfamily of nuclear receptors that regulate GENETIC TRANSCRIPTION of a diverse group of GENES involved in the synthesis of BLOOD COAGULATION FACTORS; and in GLUCOSE; CHOLESTEROL; and FATTY ACIDS metabolism.
] |
|
Genes, p53
|
G05.360.340.024.340.415.400.385 |
|
|
National Longitudinal Study of Adolescent Health
|
N06.850.520.450.500.750.500.500 |
|
|
Ulnar Collateral Ligament Reconstruction
|
E02.718.750 |
|
